Antidepressants: gradual and accompanied withdrawal avoids relapse risk

Many patients hesitate to stop antidepressants due to fears of withdrawal syndrome or symptom relapse. A study published in The Lancet shows that a gradual withdrawal, combined with psychological support, does not increase relapse risk compared to continuing the treatment.

Stopping antidepressants often poses a major challenge for patients with depressive or anxiety disorders. Many extend their treatment for years, fearing the return of symptoms or the effects of poorly managed withdrawal. A recent study, conducted by French experts and published on December 11, 2025, in The Lancet, provides reassuring insights on this issue.

The research compares two approaches: continuing the treatment and a gradual withdrawal accompanied by psychological support. The findings show that both methods are equally safe, with similar relapse risks. They are far preferable to an abrupt interruption or rapid dose reduction, which heighten complications.

Florian Naudet, professor at the University of Rennes and lead author of the study, states: “These two strategies – cautious withdrawal and continuing the treatment – are both safer than an abrupt interruption and a rapid reduction of antidepressants. Patients who are considering it should know that it is possible to stop, provided it is done within a shared decision with their doctor and with proper support.”

This publication highlights the importance of a shared decision between patient and physician, along with tailored support. It may encourage more individuals to consider a controlled withdrawal, while avoiding the pitfalls of a hasty cessation. The researchers emphasize the need for personalized follow-up to minimize risks associated with long-term treatments.

Related Articles

Realistic illustration showing a woman exercising joyfully, equating exercise to therapy and antidepressants for depression relief per Cochrane review.
Image generated by AI

Exercise can ease depression symptoms about as much as therapy, Cochrane review finds

Reported by AI Image generated by AI Fact checked

An updated Cochrane review of randomized trials suggests exercise can reduce depressive symptoms compared with no treatment and may perform about as well as psychological therapy. Results were also similar to antidepressants, though the evidence there is less certain, and researchers say larger, higher-quality studies are still needed.

A new Cochrane Library review of dozens of trials confirms that regular exercise can alleviate depression symptoms as effectively as antidepressants or cognitive behavioral therapy. Even light activities like walking may provide significant benefits. Researchers analyzed nearly 5,000 adults with depression, finding moderate reductions in symptoms across various exercise types.

Reported by AI

A new study reveals that despite guidelines, about one in four Medicare beneficiaries with dementia continue to receive brain-altering medications linked to falls and confusion. Prescribing rates have declined overall from 20% to 16% between 2013 and 2021, but those with cognitive impairment face higher risks. Researchers highlight the need for better documentation and alternatives to improve care safety.

Anxiety often appears subtly as constant unease or physical tension, and it is not defeated by fighting it but by regulating it with understanding. Techniques like conscious breathing and sensory grounding help activate calm and bring the mind to the present. Applied consistently, these practices allow managing anxiety without it dominating daily life.

Reported by AI

A Department of Health report on December 29 revealed that the National Center for Mental Health received 675 calls since December 21. Most callers were aged 18 to 30 and female, citing anxiety, depression, relationship issues, and family problems. A clinical psychologist offered advice on managing the emotional load during the holidays.

Medications such as semaglutide (marketed as Ozempic/Wegovy) could aid treatment of alcohol and other substance use disorders, according to a peer‑reviewed review in the Journal of the Endocrine Society. Early animal and human data suggest these GLP‑1 receptor agonists act on brain reward circuits; lead author Lorenzo Leggio urged caution, saying, “Early research in both animals and humans suggests that these treatments may help reduce alcohol and other substance use.”

Reported by AI Fact checked

A preliminary analysis presented at the American Heart Association’s Scientific Sessions 2025 found that adults with chronic insomnia who used melatonin for a year or longer had higher rates of new heart failure, heart‑failure hospitalization and all‑cause death over five years than matched nonusers. The observational findings do not prove causation and are not yet peer‑reviewed.

 

 

 

This website uses cookies

We use cookies for analytics to improve our site. Read our privacy policy for more information.
Decline